Skip to main content

Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity

Objective

The development of anti-drug antibodies is the major complication of treatment with biotherapeutics. This is particularly true
of patients with haemophilia A (HA) who develop neutralizing antibodies to therapeutic factor VIII (FVIII) following
replacement therapy with exogenous pro-coagulant FVIII. The onset of neutralizing antibodies to FVIII, referred to as FVIII
inhibitors, represents a major societal concern owing to the enormous cost associated to the clinical management of
inhibitor-positive patients, that exceeds 200,000€/patient/year. The EDUC8 program is a multidisciplinary training program
with exposure of the enrolled ESRs to a core common educational package and development of individual PhD research
projects dedicated to decreasing the societal burden associated with the development of anti-FVIII antibodies in Europe. The
core educational program includes exposure to basic science in the fields of immunology and hemostasis, to the most
advanced “omic” technologies in order to anticipate tomorrow’s scientific discoveries, and to the importance of ethical
considerations and public awareness in today’s research. A key component of the training program is provided by immersion
of the ESRs in a clinical center for HA, which will provide them with a unique experience and foster the conception of novel
and realistic therapeutic approaches. The ESRs will exploit the accumulated theoretic and practical experience in an
entrepreneurship training on key strategic, technical, financial and human resource issues required for the creation of startups.
In a tribute to the concept of the fully developed mind coined by the French philosopher Michel de Montaigne on
education, our ambition is to form a novel generation of scientists with deep scientific knowledge, multicultural exposure,
imagination, pragmatism and understanding of both the academic and private sectors. This will foster translational research in European on the immunogenicity of therapeutic proteins.

Call for proposal

H2020-MSCA-ITN-2019
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France
Activity type
Research Organisations
EU contribution
€ 274 802,04

Participants (7)

Stichting Sanquin Bloedvoorziening
Netherlands
EU contribution
€ 265 619,88
Address
Plesmanlaan 125
1006 AN Amsterdam
Activity type
Research Organisations
UNIVERSITA DEGLI STUDI DI MILANO
Italy
EU contribution
€ 261 499,68
Address
Via Festa Del Perdono 7
20122 Milano
Activity type
Higher or Secondary Education Establishments
JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN
Germany
EU contribution
€ 252 788,40
Address
Theodor W Adorno Platz 1
60323 Frankfurt Am Main
Activity type
Higher or Secondary Education Establishments
UNIVERSITATSKLINIKUM BONN
Germany
EU contribution
€ 252 788,40
Address
Venusberg-campus 1
53127 Bonn
Activity type
Higher or Secondary Education Establishments
DC4U
Netherlands
EU contribution
€ 265 619,88
Address
De Corridor 21E
3621 ZA Breukelen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TOPAS THERAPEUTICS GMBH
Germany
EU contribution
€ 252 788,40
Address
Falkenried 88 Haus B
20251 Hamburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
France
EU contribution
€ 274 802,04
Address
Rue Leblanc 25
75015 Paris 15
Activity type
Research Organisations